Herbas VPB

Print
EN | LT
LT - ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR
EN - ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR

Legal status

Patent not validated

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. C07D 405/14
C07D 403/04
C07D 405/04
C07D 239/42
A61K 31/506
A61P 25/00
European patent
(11) Number of the document 2909201
(13) Kind of document T
(96) European patent application number 13785389.1
Date of filing the European patent application 2013-10-21
(97) Date of publication of the European application 2015-08-26
(45) Date of publication and mention of the grant of the patent 2017-02-22
(46) Date of publication of the claims translation
PCT application
(86) Number PCT/EP2013/071947
Date 2013-10-21
PCT application publication
(87) Number WO 2014/064038
Date 2014-05-01
Priority applications
(30) Number Date Country code
201261716824 P 2012-10-22 US
201361777114 P 2013-03-12 US
Inventors
(72)
HAUPT, Andreas, DE
DINGES, Jürgen, US
UNGER, Liliane, DE
WICKE, Karsten, DE
VAN WATERSCHOOT, Robert, CH
MITTELSTADT, Scott, US
DRESCHER, Karla, DE
RELO, Ana, DE
Grantee
(73) AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064, US
AbbVie Deutschland GmbH & Co. KG, Mainzer Strasse 81, 65189 Wiesbaden, DE
Title
(54) ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR
  ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR
Last update date 2021-04-30